Session 89 - 12th CROI

Home

Session 89 Poster Abstracts
Enhancing Immune Responses to Vaccines
Wednesday, 1:30 - 3:30 pm
Hall D

493	Plasmid Vaccines Containing Engineered IL-12 or IL-15 Drive High Levels of CD8 Antigen-Specific Effector Cells with Different Immunological Profiles J Boyer¹, Sandra Calarota*¹, M Kutzler¹, E Nietrzeba¹, S Kumar¹, R Parkinson¹, V Roopchand², M Sidhu², M Lewis³, P Silvera⁴, G Pavalkis⁵, K Muthumani¹, T Waldman⁵, and D Weiner¹ ¹Univ of Pennsylvania, Philadelphia, USA; ²Vaccines Discovery, Wyeth, Pearl River, NY, USA; ³Bioqual, Inc, Rockville, MD, USA; ⁴Southern Res Inst, Frederick, MD, USA; and ⁵NCI, NIH, DHHS, Bethesda, MD, USA
494	HLA-driven Optimization of an HIV Vaccine Immunogen V Jojic¹, D Heckerman¹, C Kadie¹, C Meek¹, C Moore², M John², and S Mallal² ¹Microsoft Res, Redmond, WA, USA and ²Royal Perth Hosp, Australia
495	Enhancing Responses to DNA Vaccination Using Plasmids for Soluble, Multimeric CD40 Ligand and Glucocorticoid-induced Tumor Necrosis Factor Receptor Ligand G Stone¹, S Barzee¹, V Snarsky¹, K Kee¹, X F Yu², and Richard Kornbluth*¹ ¹Univ of California, San Diego, USA and ²John Hopkins Sch of Hygiene & Publ Hlth, Baltimore, MD, USA
496	Novel Bacteria-derived Glycolipids and Sulfatide Analogs Are Potential HIV Vaccine Adjuvants That Act through Stimulation of CD1d-Restricted natural Killer T Cells M Poles^1,2, A Horowitz¹, D Wu³, G W Xing³, Y Kinjo⁴, B Sullivan⁴, O Plettenburg³, M Kronenberg⁴, C H Wong³, D Ho¹, and Moriya Tsuji*^1,2 ¹Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, USA; ²New York Univ Sch of Med, NY, USA; ³The Scripps Res Inst, La Jolla, CA, USA; and ⁴La Jolla Inst of Allergy and Immunology, San Diego, CA, USA